The FDA recently granted QRX003 Orphan Drug Designation for the treatment of NS. The European Medicines Agency had granted Orphan Drug Designation to QRX003 earlier. The company believes these designations reinforce the potential of QRX003 as a therapeutic candidate and could shorten the time to potentially attain regulatory approval & accelerate the timeline to market and commercial prospects. Moreover, with the company advancing its investigator led pediatric NS study and advancing other assets, including Rapamycin, QNRX is expanding its potential opportunities, we believe.
